Table 1 DNA damage measured by the Comet assay in PBMCs isolated from blood of apparently healthy donors (N), unselected BC patients and cancer patients with adverse skin reaction to RT after exposure to 5 Gy of X-irradiation in vitro^a

From: Radiosensitivity in breast cancer assessed by the Comet and micronucleus assays

Subject ^b	Age (years)	Sex	Smoking status ^c	Clinical status with respect to cancer, skin reaction to RT ^d	0 Gy, TM (AU)	Total initial TM, TM _IT (AU)	Residual TM, TM _R (AU)	Repair half-time (min)
Apparently healthy donors
N-1	26	F	—	ND	0.44	7.11	0.69	5.81
N-2	27	F	—	ND	0.38	11.39	2.20	2.23
N-3	39	M	—	ND	0.60	11.97	0.76	4.51
N-4	30	F	—	ND	0.48	7.34	0.80	7.39
N-5	51	F	—	ND	0.57	10.37	0.61	3.80
N-6	32	M	10/day	ND	0.69	11.17	0.81	4.40
N-7	31	M	—	ND	0.37	9.76	0.97	2.64
N-8	25	M	—	ND	0.44	13.42	0.60	5.74
N-9	24	M	—	ND	0.26	14.22	0.73	5.08
N-10	27	F	—	ND	0.45	8.40	0.74	3.89
N-11	25	F	—	ND	0.43	8.38	1.43	7.63
N-12	62	F	—	ND	0.74	9.75	1.27	4.26
N-13	49	F	—	ND	0.48	11.06	1.10	4.84
N-14	67	F	—	ND	0.36	10.20	1.10	0.48
N-15	66	F	—	ND	0.61	10.05	0.63	6.05
N-16	77	F	—	ND	0.59	10.0	1.67	4.78
Mean	41				0.49	10.30	1.0	4.60
±s.d.	18				0.13	2.0	0.45	1.82
BC patients
001	62	F	5–10/day	BC, grade 2	0.62	9.82	1.38	4.30
002	63	F	—	BC, grade 2	1.09	12.34	1.41	6.89
003	68	F	—	BC, grade 1	0.97	8.61	0.79	4.71
004	65	F	—	BC, grade 1	0.42	12.74	1.00	5.70
005	58	F	—	BC, grade 2	0.36	12.52	1.07	4.41
006	79	F	—	BC, grade 1	0.27	9.71	0.62	4.50
008	64	F	—	BC, grade 1	0.39	15.05	0.69	6.27
009	47	F	10/day	BC, grade 1	0.29	10.14	0.75	10.45
010	75	F	—	BC, grade 1	0.39	11.01	0.10	13.27
012	58	F	—	BC, grade 2	0.83	17.96	1.03	3.67
013	55	F	—	BC, grade 1	0.42	11.99	1.30	4.46
014	73	F	—	BC, grade 1	0.48	10.81	1.29	2.11
015	72	F	—	BC, grade 1	0.55	6.36	0.83	7.04
016	66	F	—	BC, grades 2 and 3	0.71	13.87	1.01	4.04
017	56	F	—	BC, grade 1	0.23	9.18	0.80	5.28
018	55	F	10–15/day	BC, grade 0 and 1	0.36	6.03	0.83	3.46
019	69	F	—	BC, grade 0 and 1	0.50	6.25	0.26	9.27
020	75	F	—	BC, grade 0 and 1	0.45	7.40	0.93	5.86
021	69	F	—	BC, grades 2 and 3	0.32	6.08	0.60	3.23
022	62	F	—	BC, grade 1	0.27	10.13	0.76	3.87
023	63	F	—	BC, grade 1	0.45	8.92	1.19	6.60
024	70	F	—	BC, grade 1	0.34	7.25	1.25	2.77
025	54	F	2–5/day	BC, grade 1	0.33	5.90	0.81	4.41
026	74	F	—	BC, grade 0	0.26	4.78	0.74	4.13
027	38	F	—	BC, grade 2	0.55	12.36	0.64	8.25
028	59	F	—	BC, grade 1	0.94	13.81	1.52	9.56
029	67	F	—	BC, grade 2	0.45	9.89	0.98	5.75
030	63	F	—	BC, grade 1	0.78	12.65	1.21	4.21
031	47	F	15–20/day	BC, grade 1	0.69	14.58	2.63	4.20
032	68	F	—	BC, grade 0	0.73	14.65	2.37	3.29
033	70	F	—	BC, grade 1	0.56	8.10	0.66	9.93
034	75	F	—	BC, grade 1	0.78	8.59	1.0	7.02
035	54	F	—	BC, grade 1	0.41	11.68	1.11	4.45
036	48	F	—	BC, grade 1	0.31	9.27	1.07	3.17
037	58	F	—	BC, grade 1	0.34	6.26	0.65	4.09
038	75	F	2–5/day	BC, grade 1	0.37	11.21	1.32	3.38
039	60	F	—	BC, grade 2	0.47	13.26	1.21	4.30
040	54	F	—	BC, grade 2	0.67	12.7	1.45	4.52
041	45	F	—	BC, grade 1	0.41	12.53	1.35	4.40
042	57	F	—	BC, grade 1	0.66	10.61	0.88	6.33
043	41	F	—	BC, grade 2	0.33	8.05	0.89	3.76
044	67	F	—	BC, grade 1	0.65	11.1	0.87	2.99
045	61	F	—	BC, grades 0 and 1	0.31	13.07	1.09	6.22
046	69	F	—	BC, grade 1	0.27	9.19	0.43	7.31
047	55	F	6–8/day	BC, grade 2	0.34	7.93	0.48	6.10
048	61	F	—	BC, grade 2	0.64	15.18	1.52	7.02
049	71	F	—	BC, grade 1	0.51	10.17	0.81	5.47
050	60	F	20/day	BC, grade 1	0.40	8.96	1.13	3.94
051	43	F	2–3/day	BC, grade 2	0.39	9.26	1.02	3.26
052	56	F	—	BC, grade 1	0.31	15.43	1.02	5.42
Mean	61				0.49	10.50	1.02	5.38
±s.d.	10				0.20	3.0	0.43	2.23
						NS	NS	NS
Cancer patients with adverse skin reaction to RT
SC1	43	F	—	BC, grades 2 and 3	0.29	8.52	0.73	7.20
SC2	50	M	—	TC, grades 2 and 3	2.18	9.71	1.77	5.51
SC3	49	F	5–10/day	BC, grades 2 and 3	1.0	9.15	0.79	10.09
SC4	49	M	—	BC, grades 2 and 3	0.51	7.74	1.13	5.29
SC5	64	M	—	PC, grades 2 and 3	0.31	10.77	1.16	2.17
SC6	52	F	2–5/day	BC, grade 3	0.61	6.87	1.01	5.50
SC7	49	F	—	BC, grades 2 and 3	0.29	12.08	0.74	5.40
SC8	63	F	—	BC, grades 2 and 3	0.59	7.02	1.28	2.74
SC9	69	F	—	BC, grades 2 and 3	0.36	16.92	1.38	2.35
Mean	54				0.68	9.9	1.1	5.14
±s.d.	9				0.61	3.2	0.3	2.53

BC=breast cancer; F=female; M=male; N=normal; ND=not determined; PBMC=peripheral blood mononuclear cells; PC=plasmacytoma; RT=radiotherapy; SC=sensitive case; TC=tongue carcinoma.
Each indicated DNA damage parameter represents the mean value obtained on the cells from a given individual. Significance was established using Student's t-test. P compares the differences between tested group and apparently healthy individuals. NS indicates that the difference was not highly significant (P>0.05). Bold fonts indicate the unselected BC patients who revealed an adverse skin reaction to RT.
^bCase number was according to our files.
^c‘—’ means nonsmoker, the numbers indicate the amounts of smoked cigarettes per day.
^dEarly skin reaction according RTOG score (Cox et al, 1995). RTOG grade: 1 – follicular, faint or dull erythema, dry desquamation; 2 – tender or bright erythema, moderate oedema; 3 – confluent, moist desquamation, pitting oedema; 4 – ulceration, haemorrhage, necrosis.

Back to article page

Table 1 DNA damage measured by the Comet assay in PBMCs isolated from blood of apparently healthy donors (N), unselected BC patients and cancer patients with adverse skin reaction to RT after exposure to 5 Gy of X-irradiation in vitro^a

Search

Quick links